To elucidate the pathophysiology of RTT and identify potential therapeutic targets, multiple laboratories have investigated gene expression profiles in Mecp2-deficient mice, rat, and postmortem human tissue utilizing microarray as well as RNA sequencing (RNA-Seq) [4, 9, 19–34]. The gene discussed is MECP2; the disease is Rett syndrome.